Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly's Mounjaro (tirzepatide) has demonstrated superior efficacy in reducing fat mass and achieving glycemic targets in adults with type 2 diabetes compared to injectable semaglutide and placebo, as presented at the ADA's 82nd Scientific Sessions. In a 28-week study, Mounjaro participants lost an average of 11.2 kg in weight and 9.7 kg in fat mass, significantly more than those on semaglutide. Mounjaro also helped participants reach A1C targets quicker, achieving A1C <7% in 8 weeks. The drug is FDA-approved and utilizes a dual-action mechanism of GIP and GLP-1 receptor agonism.

The latest analyses from the EMPRISE study indicate that Jardiance (empagliflozin) significantly reduces the risk of hospitalization for heart failure by 50% compared to DPP-4 inhibitors and by 30% against GLP-1 receptor agonists among adults with type 2 diabetes. Furthermore, for those with Medicare, Jardiance shows a 40% reduction in all-cause mortality. The study involved nearly 500,000 adults, confirming Jardiance's effectiveness and safety profile. These findings complement the EMPA-REG OUTCOME trial results, reinforcing Jardiance's role in cardiovascular risk management for diabetic patients.

Eli Lilly's phase 3 AWARD-PEDS trial demonstrated that Trulicity (dulaglutide) significantly reduces A1C levels in youth with type 2 diabetes, achieving a reduction of up to 1.5% compared to placebo. Conducted on 154 adolescents, the trial met all primary and secondary glycemic control objectives. Notably, 51.5% of participants on Trulicity achieved an A1C of <7%. However, gastrointestinal side effects were reported more frequently than in the placebo group. Lilly plans to seek regulatory approval based on these promising results presented at the ADA's 82nd Scientific Sessions.

Eli Lilly's phase 3 SURMOUNT-1 trial results for tirzepatide, presented at the ADA's 82nd Scientific Sessions and published in NEJM, show significant weight loss in adults with obesity. Participants lost an average of 16.0% to 22.5% of body weight over 72 weeks, with 89%-96% achieving at least 5% reduction compared to 28% on placebo. Secondary endpoints also met, reinforcing tirzepatide's efficacy. Adverse events were primarily mild to moderate gastrointestinal issues, with treatment discontinuation rates lower than placebo. Lilly anticipates further results from additional SURMOUNT trials in 2023.

Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022. Key executives, Anne White and Mark Mintun, will engage in a fireside chat at 1:40 p.m. ET. Investors can listen to the event via a live audio webcast on Lilly's Investor website, with a replay available for 90 days. Founded nearly 150 years ago, Lilly is committed to advancing health solutions that positively impact over 47 million people globally. For more information, visit Lilly.com.

Eli Lilly and Company (NYSE: LLY) has announced that data from its oncology portfolio will be showcased at the 2022 ASCO Annual Meeting from June 3-7, 2022. Key presentations include analyses from the Phase 3 monarchE study of Verzenio (abemaciclib) focusing on treatment discontinuation in high-risk HR+, HER2- early breast cancer. Updates on Retevmo (selpercatinib) will highlight its efficacy in RET fusion-positive solid tumors, while results from the Phase 1 EMBER trial on the investigational drug imlunestrant will also be presented. The event promises significant insights into cancer treatment advancements.

Bigfoot Biomedical has appointed Matt Rainville as Chief Commercial Officer, aiming to enhance the Bigfoot Unity® Diabetes Management Program. With over 20 years in healthcare commercialization, including roles at Insulet and Eli Lilly, Rainville will focus on expanding access to diabetes management solutions. CEO Jeffrey Brewer emphasized that this hiring is crucial as they seek to grow their presence in the market for insulin management. Rainville's leadership is expected to drive adoption of their innovative solutions for diabetes care.

Eli Lilly and Company (NYSE: LLY) has announced a significant expansion of its manufacturing capabilities in Indiana with a $2.1 billion investment in two new sites at the LEAP Lebanon Innovation District. This initiative aims to enhance the production of active ingredients and innovative therapies, supporting a growing pipeline of medicines. The project is expected to create 500 new jobs at Lilly and 1,500 construction positions, reinforcing Lilly's pivotal role in Indiana's economy. The expansion is contingent upon local zoning approvals.

Eli Lilly's Phase 3 LUCENT-2 study on mirikizumab shows that 50% of ulcerative colitis patients achieved clinical remission after one year, with almost all not using steroids. The drug outperformed placebo across all key endpoints, with 63.6% maintaining remission. Patients reported significant reductions in bowel urgency severity, and adverse events were lower compared to placebo. Lilly seeks regulatory approvals in the US and EU in 2023, potentially positioning mirikizumab as the first anti-IL23p19 treatment for ulcerative colitis.